A recent study published in ISPOR’s Value in Health aimed to better understand the discrepancies in prescription drug spending figures cited by a number of familiar entities, including the Centers for Medicare and Medicaid Services, AHIP and the Kaiser Family Foundation.
According to a National Pharmaceutical Council blog post, failure to develop a standardized method for generating such spending figures can be detrimental for policy discussions.
“These considerable differences exemplify how policy discussions about drug spending in the U.S. can often be misinformed,” NPC states in the blog post. “These varied estimates of drug spending aren’t necessarily wrong. The estimates are each targeted for a specific research purpose, none of which are directly comparable.”
To read the full blog post on NPC’s website, click here.